This retrospective study provided evidence on the efficacy of immunotherapies in advanced EGFR‐mutated NSCLC patients who failed to respond to EGFR‐TKIs and multiple conventional systemic therapies in a real‐world setting. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.